statin deprescribing
Jump to navigation
Jump to search
Indications
- limited prognosis, palliative care[1]
Contraindications
- in elderly patients receiving statin, antihypertensive(s), hypoglycemic(s) & antiplatelet agent(s) (mean age 76 years, cardiovascular disease implied by medications), deprescribing statin while maintaining other medications is associated with increased risk for adverse cardiovascular outcome(s) (RR=1.14)[2]*
- among elderly >= 75 years with >= 5 years of statin therapy, discontinuation of statin associated with higher risk of major cardiovascular event[3]
- relative risk; 1.32 (primary prevention); 1.28 (secondary prevention)[3]
* senior author with conflict of interest disclosures[2]
More general terms
Additional terms
References
- ↑ 1.0 1.1 Kutner JS et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med 2015 May; 175:691 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25798575
- ↑ 2.0 2.1 2.2 Rea F, Biffi A, Ronco R et al Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. JAMA Netw Open. 2021;4(6):e2113186 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34125221
- ↑ 3.0 3.1 3.2 Thompson W, Morin L, Jarbol DE et al Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA Netw Open. 2021 Dec 1;4(12):e2136802. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34854906 PMCID: PMC8640890 Free PMC article.